Discover how IQVIA Laboratories is transforming biomarker quantitation with a validated TL1A assay using nano-LC and high-resolution mass spectrometry (HRMS). This white paper highlights TL1A’s role in autoimmune diseases and introduces a breakthrough method for detecting low picogram-per-milliliter concentrations with unmatched sensitivity and specificity. Learn how this platform supports precision medicine, regulatory compliance, and scalable biomarker discovery.
Complete the form below to download this white paper and explore the future of biomarker analysis.
Related Insights
The End to End Importance of Selecting the Right Biomarker in Cancer Studies
A critical component in the fight against cancer and optimizing treatment outcomes for patients
IQVIA Laboratories Biomarker Services
Providing tools and experience to maximize your biomarker strategy
Biomarker roadmap to success
Develop a biomarker roadmap for a successful strategy in developing targeted therapies
Building a Best-in-Class Model for Global CDx Clinical Trial Deployment
11th Annual World Clinical Biomarkers & CDx Summit
Translational Science and Innovation Laboratory (TSAIL)
Translational biomarker solutions to accelerate the adoption of assays into clinical trials though new technology evaluation and early biomarker discovery
Alzheimer’s Disease Clinical Trials
Innovative laboratory solutions to accelerate progress
Selection of Biomarkers for Immuno-Oncology with Patrice Hugo
I-O clinical development podcast series
Biomarker-Driven Trials: How Laboratory Insight Can Enhance Clinical Trial Design and Optimize Drug Development
Diabetes Solutions
Learn how we support our customers across the development continuum in their fight against the global diabetes epidemic.
Next Generation Immuno-Oncology Flow Cytometry with Mark Edinger
I-O clinical development podcast series
